CG Oncology (CGON) Non-Current Debt (2025 - 2026)
CG Oncology (CGON) posted Non-Current Debt of $3.0 million for Q1 2026, little changed on a QoQ basis from $3.0 million in Q4 2025.
CG Oncology (CGON) Non-Current Debt (2025 - 2026) Analysis & Trends
CG Oncology's Non-Current Debt history runs 2 years deep, the most recent figure standing at $3.0 million for Q1 2026.
- Quarterly Non-Current Debt changed N/A year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 million (changed N/A YoY) and the FY2025 annual result came in at $3.0 million, changed N/A from the prior year.
- Non-Current Debt was $3.0 million for Q1 2026 at CG Oncology, roughly flat from $3.0 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $3.0 million in Q3 2025 and bottomed at $3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 105.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 842.92 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | CG Oncology | 5.86 Bn | 5.86 Bn | -1.88 Mn | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.00 Mn |
| Dec 31, 2025 | 3.00 Mn |
| Sep 30, 2025 | 3.00 Mn |